GGHC
CRDF icon

Gilder Gagnon Howe & Co’s Cardiff Oncology CRDF Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-526
Closed -$384K – 264
2015
Q2 		$384K Buy
+526
New +$373K 0.01% 238

Other funds holding CRDF

BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MWVC
Morgens Waterfall Vintiadis & Co New York $81.2M AUM 86.87% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Gilder Gagnon Howe & Co's CRDF Position: Q3 2015 in Review

Gilder Gagnon Howe & Co sold out of Cardiff Oncology (CRDF) in Q3 2015, closing a stake of 526 shares — an estimated $384K sold.

Gilder Gagnon Howe & Co first reported a position in CRDF in Q2 2015 and held it in 1 quarter. The position peaked at $384K in Q2 2015. 60 funds tracked by Wall St. Rank hold CRDF as of Q3 2015.

  • Gilder Gagnon Howe & Co reported no remaining Cardiff Oncology position as of Q3 2015 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 526 Cardiff Oncology shares in Q3 2015, an estimated $384K.
  • Gilder Gagnon Howe & Co first reported a position in Cardiff Oncology in Q2 2015 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's Cardiff Oncology position peaked at $384K in Q2 2015.
  • 60 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2015.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2015, filed 9 Nov 2015.